BiotechTube

AFM24 + Atezolizumab 840 MG in 14 ML Injection

Phase 1/2Terminated
0 views this week 0 watching💤 Quiet
Interest: 14/100
14
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Advanced Solid Tumor

Conditions

Advanced Solid Tumor

Trial Timeline

Nov 19, 2021 → Jun 11, 2025

NCT ID
NCT05109442

About AFM24 + Atezolizumab 840 MG in 14 ML Injection

AFM24 + Atezolizumab 840 MG in 14 ML Injection is a phase 1/2 stage product being developed by Affimed for Advanced Solid Tumor. The current trial status is terminated. This product is registered under clinical trial identifier NCT05109442. Target conditions include Advanced Solid Tumor.

What happened to similar drugs?

16 of 20 similar drugs in Advanced Solid Tumor were approved

Approved (16) Terminated (1) Active (4)
✅ApatinibTabletsJiangsu Hengrui MedicineApproved
✅letrozoleJiangsu Hengrui MedicineApproved
✅Levodopa-carbidopa intestinal gel (LCIG)AbbVieApproved
✅FulvestrantAstraZenecaApproved
✅Zoladex and CasodexAstraZenecaApproved
✅GefitinibAstraZenecaApproved
✅Alpelisib + FulvestrantNovartisApproved

Hype Score Breakdown

Clinical
9
Activity
0
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05109442Phase 1/2Terminated

Competing Products

20 competing products in Advanced Solid Tumor

See all competitors
ProductCompanyStageHype Score
mRNA-4359ModernaPhase 2
0
mRNA-4106ModernaPhase 1
0
AK-105AkesoPhase 1
29
EXS21546BiotrialPhase 1/2
14
SY-1365 (Part 1) + Carboplatin + Fulvestrant + SY-1365 (Cohort 2) + SY-1365 (Cohort 5) + SY-1365 (Part 2 Single Agent)Syros PharmaceuticalsPhase 1
11
Necitumumab + Gemcitabine + CarboplatinEli LillyPhase 2
27
Pemetrexed + Erlotinib + Pemetrexed + ErlotinibEli LillyPhase 2
35
NBTXR3NanobiotixPhase 1/2
33
pegfilgrastim + LY2523355Eli LillyPhase 1
29
SON-1010Sonnet BioTherapeuticsPhase 1
27
SON-1010Sonnet BioTherapeuticsPhase 1/2
18
BT1718Bicycle TherapeuticsPhase 1/2
22
Zentalis + GemzarZentalis PharmaceuticalsPhase 2
29
IMC-18F1Eli LillyPhase 1
29
Tadalafil + GemcitabineEli LillyPhase 1
29
OKI-179OnKure TherapeuticsPhase 1
19
OKI-219 + Fulvestrant + Trastuzumab + Tucatinib + Atirmociclib + RibociclibOnKure TherapeuticsPhase 1
26
LY3499446 + Abemaciclib + Cetuximab + Erlotinib + DocetaxelEli LillyPhase 1/2
24
LY3434172Eli LillyPhase 1
21
ACR-2316Acrivon TherapeuticsPhase 1
26